These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26952039)

  • 21. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLK1 Inhibition Sensitizes Breast Cancer Cells to Radiation via Suppressing Autophagy.
    Wang B; Huang X; Liang H; Yang H; Guo Z; Ai M; Zhang J; Khan M; Tian Y; Sun Q; Mao Z; Zheng R; Yuan Y
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1234-1247. PubMed ID: 33621661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BMI-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway.
    Yang XX; Ma M; Sang MX; Zhang XY; Liu ZK; Song H; Zhu SC
    Oncol Rep; 2018 Feb; 39(2):667-678. PubMed ID: 29207170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
    Xin X; Lin F; Wang Q; Yin L; Mahato RI
    ACS Appl Mater Interfaces; 2019 Apr; 11(16):14647-14659. PubMed ID: 30933478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
    Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
    Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
    Fan P; Zhang S; Tian H; Yan N; Dai L; Zhang X; Cheng L; Li C; Li Y; Chen X; Shi G; Yang Y; Wei Y; Deng H
    Neoplasma; 2012; 59(6):676-84. PubMed ID: 22862168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T; Tabuchi Y; Hayashi A; Kondo T
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diisopropylamine dichloroacetate enhances radiosensitization in esophageal squamous cell carcinoma by increasing mitochondria-derived reactive oxygen species levels.
    Dong G; Chen Q; Jiang F; Yu D; Mao Q; Xia W; Shi R; Wang J; Xu L
    Oncotarget; 2016 Oct; 7(42):68170-68178. PubMed ID: 27626688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vanillin derivative 6-bromine-5-hydroxy-4-methoxybenzaldehyde induces aberrant mitotic progression and enhances radio-sensitivity accompanying suppression the expression of PLK1 in esophageal squamous cell carcinoma.
    Gu MM; Li M; Gao D; Liu LH; Lang Y; Yang SM; Ou H; Huang B; Zhou PK; Shang ZF
    Toxicol Appl Pharmacol; 2018 Jun; 348():76-84. PubMed ID: 29679654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Dill V; Kauschinger J; Hauch RT; Buschhorn L; Odinius TO; Müller-Thomas C; Mishra R; Kyncl MC; Schmidt B; Prodinger PM; Hempel D; Bellos F; Höllein A; Kern W; Haferlach T; Slotta-Huspenina J; Bassermann F; Peschel C; Götze KS; Waizenegger IC; Höckendorf U; Jost PJ; Jilg S
    Eur J Haematol; 2020 Feb; 104(2):125-137. PubMed ID: 31758597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
    Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
    Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
    Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
    Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
    Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
    Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
    World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
    Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
    Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
    de Oliveira JC; Brassesco MS; Pezuk JA; Morales AG; Valera ET; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
    J Drugs Dermatol; 2012 May; 11(5):587-92. PubMed ID: 22527426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.